• 1. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 2. Alternative synthesis of the anti-baldness compound RU58841?
  RSC Adv., 2014,4, 14143-14148
• 3. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 4. Aggregation kinetics and gel formation in modestly concentrated suspensions of oppositely charged model ceramic colloids: a numerical study
  M. A. Piechowiak,A. Videcoq,R. Ferrando,D. Bochicchio,C. Pagnoux,F. Rossignol Phys. Chem. Chem. Phys., 2012,14, 1431-1439
• 5. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324

Introduction to 3-(4-methylpyridin-2-yl)propan-1-ol (CAS No: 61744-46-5)

3-(4-methylpyridin-2-yl)propan-1-ol, identified by the Chemical Abstracts Service Number (CAS No) 61744-46-5, is a significant compound in the realm of pharmaceutical and chemical research. This compound belongs to the class of pyridine derivatives, which are widely recognized for their diverse biological activities and potential applications in medicinal chemistry. The structural motif of 3-(4-methylpyridin-2-yl)propan-1-ol incorporates a pyridine ring substituted with a methyl group at the 4-position and an hydroxyl-bearing propyl chain at the 2-position, making it a versatile scaffold for further chemical modifications and biological evaluations.

The compound's unique structural features have garnered attention in recent years, particularly in the context of drug discovery and development. Pyridine derivatives are well-documented for their role as pharmacophores in various therapeutic agents, including antiviral, antibacterial, and anticancer drugs. The presence of the 4-methylpyridin moiety enhances the compound's lipophilicity, which is a critical factor in drug absorption and distribution. Additionally, the propan-1-ol side chain introduces a polar hydroxyl group, which can participate in hydrogen bonding interactions, influencing both the compound's solubility and its binding affinity to biological targets.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the binding modes of 3-(4-methylpyridin-2-yl)propan-1-ol with high precision. These studies suggest that the compound may interact with enzymes and receptors involved in metabolic pathways relevant to inflammation and neurodegeneration. For instance, preliminary docking studies have indicated potential interactions with cyclooxygenase (COX) enzymes, which are key players in the biosynthesis of prostaglandins—a class of signaling molecules involved in pain and inflammation. This finding aligns with ongoing research efforts to develop novel anti-inflammatory agents with improved efficacy and reduced side effects.

The synthesis of 3-(4-methylpyridin-2-yl)propan-1-ol involves multi-step organic reactions, typically starting from commercially available pyridine precursors. One common synthetic route involves the alkylation of 2-amino-4-methylpyridine with 1-bromopropane under basic conditions, followed by reduction to yield the desired alcohol. This method leverages well-established coupling reactions such as Suzuki or Buchwald-Hartwig couplings, depending on the specific synthetic strategy employed. The optimization of reaction conditions is crucial to achieving high yields and purity, particularly when targeting pharmaceutical-grade material.

In terms of pharmacological activity, 3-(4-methylpyridin-2-yl)propan-1-ol has been investigated for its potential role as an intermediate in the synthesis of more complex bioactive molecules. Its structural flexibility allows for further derivatization, enabling the creation of libraries of compounds for high-throughput screening (HTS). Such libraries are instrumental in identifying lead compounds with desirable pharmacological properties before proceeding to more costly and time-consuming preclinical studies.

The compound's solubility profile presents both opportunities and challenges for formulation development. While the hydroxyl group enhances water solubility compared to purely hydrophobic pyridine derivatives, achieving optimal solubility for oral or injectable formulations may require additional modifications or co-solvents. Advances in solvent-based delivery systems, such as micellar nanoparticles or lipid-based carriers, have shown promise in enhancing the bioavailability of poorly soluble drugs like 3-(4-methylpyridin-2-yl)propan-1-ol.

From an industrial perspective, scaling up the production of 3-(4-methylpyridin-2-yl)propan-1-ol requires careful consideration of cost-efficiency and environmental impact. Green chemistry principles are increasingly being applied to minimize waste and reduce energy consumption during synthesis. For example, catalytic methods that employ recyclable ligands or solvent-free reactions can significantly improve sustainability without compromising yield or purity.

The regulatory landscape for compounds like 3-(4-methylpyridin-2-yloxy)-propanal, particularly those intended for pharmaceutical use, is stringent. Compliance with Good Manufacturing Practices (GMP) ensures that all aspects of production—from raw material sourcing to final product testing—are conducted under controlled conditions to guarantee consistency and safety. Additionally, toxicological studies are essential to assess potential adverse effects before human clinical trials can commence.

Future research directions for 3-(4-methylpyridin)-2-propanol may explore its role as a building block for next-generation therapeutics targeting emerging diseases or chronic conditions. The integration of artificial intelligence (AI) into drug discovery pipelines has accelerated the identification of novel molecular structures with therapeutic potential. By leveraging machine learning algorithms trained on large datasets of bioactive compounds, researchers can predict new applications for existing molecules like 3-(4-methylpyridin)-2-propanol, potentially uncovering untapped therapeutic value.

In conclusion,3-(4-methylpyridin)-2-propanol (CAS No: 61744 46 5) represents a fascinating subject of study within pharmaceutical chemistry due to its structural complexity and biological relevance. Its synthesis methods continue to evolve alongside advancements in organic chemistry techniques, while its pharmacological potential remains an active area of investigation across academic institutions worldwide, contributing significantly to our understanding of disease mechanisms and therapeutic interventions.

• 2859-68-9(2-Pyridinepropanol)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)